Avrobio (Avrobio) Debt-to-Equity : 0.01 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Avrobio Debt-to-Equity?

Avrobio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.88 Mil. Avrobio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Avrobio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $94.74 Mil. Avrobio's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Avrobio's Debt-to-Equity or its related term are showing as below:

AVRO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.09 Max: 0.22
Current: 0.01

During the past 8 years, the highest Debt-to-Equity Ratio of Avrobio was 0.22. The lowest was 0.01. And the median was 0.09.

AVRO's Debt-to-Equity is ranked better than
99.91% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs AVRO: 0.01

Avrobio Debt-to-Equity Historical Data

The historical data trend for Avrobio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avrobio Debt-to-Equity Chart

Avrobio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.09

0.22

0.01

Avrobio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.22	0.35	0.02	0.02	0.01

Competitive Comparison of Avrobio's Debt-to-Equity

For the Biotechnology subindustry, Avrobio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avrobio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avrobio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Avrobio's Debt-to-Equity falls into.

Avrobio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Avrobio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.878	+	0)	/	94.739
	=	0.01

Avrobio's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.878	+	0)	/	94.739
	=	0.01

Avrobio (NAS:AVRO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Avrobio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Avrobio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Avrobio (Avrobio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avrobio Inc (NAS:AVRO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Technology Square, Sixth Floor, Cambridge, MA, USA, 02139

Website

https://www.avrobio.com

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.

Executives

Azadeh Golipour	officer: Chief Technology Officer	ONE KENDALL SQUARE, BLD. 300 - SUITE 201, CAMBRIDGE MA 02139
Essra Ridha	officer: Chief Medical Officer	C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG 300 - SUITE 201, CAMBRIDGE MA 02139
Philip J. Vickers	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Christopher Mason	officer: Chief Scientific Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Phillip B. Donenberg	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Diana Escolar	officer: Chief Medical Officer	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Gail M Farfel	director	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Deanna M Petersen	officer: Chief Business Officer	45 FIRST AVENUE, WALTHAM MA 02451
Geoffrey Mackay	director, officer: See Remarks	C/O AVROBIO, INC., ONE KENDALL SQ, BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Christopher Paige	director	C/O AVROBIO INC, ONE KENDALL SQ, BLDG 300, STE 201, CAMBRIDGE MA 02139
Atlas Venture Fund X, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, Llc	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p.	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund I, L.p.	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth	director	890 WINTER STREET, SUITE 320, WALTHAM MA 02451